Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Mashup Score: 28

European Urology

The KEYNOTE-365 study assessed the efficacy and safety of pembrolizumab combination therapies in metastatic castration-resistant prostate cancer (mCRPC). In cohort A, pembrolizumab plus olaparib showed antitumor activity and manageable safety in patients with molecularly unselected, docetaxel-pretreated mCRPC.

  • 123456 Profile photo of Madelyn

    Limited benefit with significant toxicity for pembro + olaparib for patients after docetaxel with mCRPC.